Explore /
Poster
/ Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.

Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.

Authors

Dietger Niederwieser

University of Leipzig, Leipzig, Germany

Dietger Niederwieser , Caroline M. Hamm , Patrick Cobb , Mindy Mo , Cecily Forsyth , Alessandra Tucci , Vladimir Hanes , Vincent Delwail , Roman Hajek , David Chien

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8044)

DOI

10.1200/JCO.2020.38.15_suppl.8044

Abstract #

8044

Poster Bd #

377

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

$Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.$

Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.

First Author: Michelle A. Fanale

Poster

2023 ASCO Annual Meeting

$SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.$